DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR ICLUSIG
➤ Get the DrugPatentWatch Daily Briefing
« Back to Dashboard
All Clinical Trials for Iclusig
| Trial ID |
Title |
Status |
Sponsor |
Phase |
Start Date |
Summary |
| NCT00660920 ↗ |
Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies |
Active, not recruiting |
Ariad Pharmaceuticals |
Phase 1 |
2008-05-01 |
The purpose of this study is to determine the maximum tolerated dose or a recommended dose
of oral AP24534 in a defined schedule (QD) in patients with refractory or advanced chronic
myelogenous leukemia and other refractory hematologic malignancies.
|
| NCT01207440 ↗ |
Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL) |
Active, not recruiting |
Ariad Pharmaceuticals |
Phase 2 |
2010-09-01 |
The purpose of this study is to determine the efficacy of ponatinib in patients with chronic
myeloid leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast phase (BP) or
with Ph positive (Ph+) acute lymphoblastic leukemia (ALL) who either are resistant or
intolerant to either dasatinib or nilotinib, or have the T315I mutation.
|
| NCT01620216 ↗ |
Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia |
Recruiting |
National Cancer Institute (NCI) |
Phase 2 |
2012-05-01 |
This phase II trial studies how well targeted therapy works in treating patients with acute
lymphoblastic leukemia or acute myelogenous leukemia that has come back after a period of
improvement or does not respond to treatment. Testing patients' blood or bone marrow to find
out if their type of cancer may be sensitive to a specific drug may help doctors choose more
effective treatments. Dasatinib, nilotinib, sunitinib malate, sorafenib tosylate, and
ponatinib hydrochloride may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth. Giving targeted therapy based on cancer type may be an effective
treatment for acute lymphoblastic leukemia or acute myelogenous leukemia.
|
| >Trial ID |
>Title |
>Status |
>Phase |
>Start Date |
>Summary |
Clinical Trial Conditions for Iclusig
Condition Name
| Condition Name for Iclusig |
| Intervention |
Trials |
| Acute Lymphoblastic Leukemia |
3 |
| Leukemia |
2 |
| Chronic Myeloid Leukemia |
2 |
| [disabled in preview] |
0 |
This preview shows a limited data set
Subscribe for full access, or try a Trial |
Condition MeSH
| Condition MeSH for Iclusig |
| Intervention |
Trials |
| Leukemia |
17 |
| Leukemia, Myeloid |
11 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma |
10 |
| [disabled in preview] |
0 |
This preview shows a limited data set
Subscribe for full access, or try a Trial |
Clinical Trial Locations for Iclusig
Trials by Country
| Trials by Country for Iclusig |
| Location |
Trials |
| United States |
53 |
| China |
13 |
| France |
7 |
| Japan |
7 |
| Canada |
6 |
This preview shows a limited data set
Subscribe for full access, or try a Trial |
Trials by US State
| Trials by US State for Iclusig |
| Location |
Trials |
| Texas |
8 |
| Oregon |
6 |
| Michigan |
4 |
| Utah |
3 |
| Massachusetts |
3 |
This preview shows a limited data set
Subscribe for full access, or try a Trial |
Clinical Trial Progress for Iclusig
Clinical Trial Phase
| Clinical Trial Phase for Iclusig |
| Clinical Trial Phase |
Trials |
| Phase 3 |
3 |
| Phase 2 |
16 |
| Phase 1/Phase 2 |
2 |
| [disabled in preview] |
0 |
This preview shows a limited data set
Subscribe for full access, or try a Trial |
Clinical Trial Status
| Clinical Trial Status for Iclusig |
| Clinical Trial Phase |
Trials |
| Recruiting |
11 |
| Not yet recruiting |
9 |
| Active, not recruiting |
2 |
| [disabled in preview] |
0 |
This preview shows a limited data set
Subscribe for full access, or try a Trial |
Clinical Trial Sponsors for Iclusig
Sponsor Name
| Sponsor Name for Iclusig |
| Sponsor |
Trials |
| Ariad Pharmaceuticals |
9 |
| M.D. Anderson Cancer Center |
4 |
| National Cancer Institute (NCI) |
3 |
| [disabled in preview] |
0 |
This preview shows a limited data set
Subscribe for full access, or try a Trial |
Sponsor Type
| Sponsor Type for Iclusig |
| Sponsor |
Trials |
| Other |
16 |
| Industry |
15 |
| NIH |
3 |
| [disabled in preview] |
0 |
This preview shows a limited data set
Subscribe for full access, or try a Trial |
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
